# VAH vs VA in Newly Diagnosed Elderly AML

> **NCT07469046** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 308 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Elderly Patients (60-75 Years)

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Homoharringtonine

## Key facts

- **NCT ID:** NCT07469046
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 308 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07469046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07469046, "VAH vs VA in Newly Diagnosed Elderly AML". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT07469046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*